Goldman Sachs
TVTX icon

Goldman Sachs’s Travere Therapeutics TVTX Stock Holding History

Goldman Sachs’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-215,000
Closed -$3.85M – 6428
2025
Q1 		$3.85M Buy
+215,000
New +$4.36M ﹤0.01% 3602
2019
Q3 		– Sell
-53,400
Closed -$1.07M – 5384
2019
Q2 		$1.07M Buy
53,400
+36,000
+207% +$711K ﹤0.01% 3953
2019
Q1 		$394K Buy
+17,400
New +$385K ﹤0.01% 4520
2018
Q4 		– Sell
-800
Closed -$23K – 5677
2018
Q3 		$23K Hold
800
– – ﹤0.01% 5402
2018
Q2 		$22K Buy
+800
New +$21.3K ﹤0.01% 5485
2018
Q1 		– Sell
-263,900
Closed -$5.56M – 6406
2017
Q4 		$5.56M Sell
263,900
-1,700
-0.6% -$38.9K ﹤0.01% 2929
2017
Q3 		$6.61M Sell
265,600
-1,800
-0.7% -$39.6K ﹤0.01% 2911
2017
Q2 		$5.18M Buy
267,400
+2,900
+1% +$52.6K ﹤0.01% 3025
2017
Q1 		$4.88M Buy
264,500
+1,100
+0.4% +$21.5K ﹤0.01% 2946
2016
Q4 		$4.99M Sell
263,400
-26,900
-9% -$550K ﹤0.01% 3055
2016
Q3 		$6.5M Buy
290,300
+286,900
+8,438% +$5.46M ﹤0.01% 2814
2016
Q2 		$61K Buy
3,400
+700
+26% +$11.3K ﹤0.01% 6346
2016
Q1 		$37K Sell
2,700
-1,448,400
-100% -$22M ﹤0.01% 6553
2015
Q4 		$28M Sell
1,451,100
-497,100
-26% -$9.93M 0.01% 1510
2015
Q3 		$39.5M Buy
1,948,200
+914,900
+89% +$27.1M 0.01% 1211
2015
Q2 		$34.3M Sell
1,033,300
-35,000
-3% -$959K 0.01% 1400
2015
Q1 		$25.6M Buy
1,068,300
+918,300
+612% +$14M 0.01% 1581
2014
Q4 		$1.84M Buy
+150,000
New +$1.55M ﹤0.01% 3931

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's TVTX Position: Q1 2026 in Review

Goldman Sachs reduced its Travere Therapeutics (TVTX) stake by 7.9% in Q1 2026, selling an estimated $4.44M and leaving 1,719,721 shares worth $51.1M. The position accounts for 0.01% of the portfolio, ranked #1567.

Goldman Sachs first reported a position in TVTX in Q3 2014 and has held it in 47 quarters since. The position peaked at $80.5M in Q4 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Goldman Sachs held 1,719,721 shares of Travere Therapeutics worth $51.1M as of Q1 2026.
  • Goldman Sachs sold 148,491 Travere Therapeutics shares in Q1 2026, an estimated $4.44M.
  • Travere Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1567 holding.
  • Goldman Sachs first reported a position in Travere Therapeutics in Q3 2014 and has held it in 47 quarters since.
  • Goldman Sachs's Travere Therapeutics position peaked at $80.5M in Q4 2021.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.